Tumor-specific, circulating cell-free DNA in liquid biopsies is a promising source of
biomarkers for minimally invasive serial monitoring of treatment responses in cancer …

Liquid biopsies (LBs), particularly using circulating tumor DNA (ctDNA), are expected to
revolutionize precision oncology and blood-based cancer screening. Recent technological …

Circulating tumour DNA (ctDNA) refers to the fraction of cell-free DNA in a patient's blood
that originates from a tumour. Advances in DNA sequencing technologies and our …

Circulating tumour nucleic acids (ctNAs) are released from tumours cells and can be
detected in blood samples, providing a way to track tumors without requiring a tissue …

Purpose To explore the feasibility and performance of machine learning-based radiomics
classifier to predict the cell proliferation (Ki-67) in non-small cell lung cancer (NSCLC) …

Simple Summary Liquid biopsy has recently been introduced as a novel method in cancer
diagnostics. It is less invasive for patients than conventional tissue biopsies, as the assay …

Abstract Background Circulating tumour DNA (ctDNA) may serve as a measure of tumour
burden and a useful tool for non-invasive monitoring of cancer. However, ctDNA is not …

Tumor cells release fragments of their DNA into the circulation, so called cell‐free tumor
DNA (ctDNA), allowing for analysis of tumor DNA in a simple blood test, that is, liquid biopsy …

Measuring total cell-free DNA (cfDNA) or cancer-specific mutations herein has presented as
new tools in aiding the treatment of cancer patients. Studies show that total cfDNA bears …

Current imaging-based cancer screening approaches provide useful but limited prognostic
information. Complementary to existing screening tests, cell-free DNA–based multicancer …